Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Tops Revenue Estimates
Portfolio Pulse from
Clearside Biomedical, Inc. (CLSD) reported a Q3 loss of $0.10 per share, which was better than the Zacks Consensus Estimate of a $0.14 loss. This is an improvement from the $0.15 loss per share reported a year ago.
November 13, 2024 | 12:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Clearside Biomedical reported a Q3 loss of $0.10 per share, beating the expected loss of $0.14 and showing improvement from last year's $0.15 loss.
The better-than-expected earnings report is likely to have a positive impact on CLSD's stock price in the short term. The improvement from last year's loss also suggests positive momentum.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100